U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT07532018) titled 'DXP-106 in Solid Tumor Patients.' on March 19.
Brief Summary: The goal of this clinical trial is to evaluate the safety and tolerability of DXP-106 in Chinese patients with advanced solid tumors. The main questions it aims to answer are:
For Part I:
1. The safety and tolerability of DXP-106 monotherapy in patients with advanced solid tumors;
2. The dose-limiting toxicities (DLTs) and determine the maximum tolerated dose (MTD) and/or the recommended Phase II dose (RP2D);
3. The pharmacokinetics (PK) profile, the immunogenicity of DXP-106 following administration in patients with advanced solid tumors;
4. The preliminary efficac...